A Maine resident is seeking class-action status for a suit accusing Elevance Health of discrimination because it declines to ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 598.51% and ...

BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed IPO. Read more here.

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established ...

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently ...

Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

Eli Lilly (LLY) stock is trading near its all-time highs, with the shares only about 5% away from the record levels set in ...

(RTTNews) - Eli Lilly and Company (LLY) Wednesday reported new long-term data for its atopic dermatitis treatment Ebglyss. The results were reported from ADjoin long-term extension study.

While several factors predict sustained glycemic control, predictors of sustained weight control with tirzepatide appear ...

In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most ...